



City Research Online

City, University of London Institutional Repository

Citation: Williams, L. J., Fisher, M., Reyes-Aldasoro, C. C., Kanthou, C. & Tozer, G. M. (2011). Abstract 1578: A critical role for RhoA-GTPase signaling in the tumor vascular disrupting action of combretastatin-A4-phosphate in vivo. *Cancer Research*, 71(8_Supplement), p. 1578. doi: 10.1158/1538-7445.am2011-1578

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/5945/>

Link to published version: <https://doi.org/10.1158/1538-7445.am2011-1578>

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online:

<http://openaccess.city.ac.uk/>

publications@city.ac.uk

A critical role for RhoA-GTPase signaling in the tumor vascular disrupting action of combretastatin-A4-phosphate *in vivo*

Leigh Williams¹, Matthew Fisher¹, Constantino C. Reyes-Aldasoro¹, Chryso Kanthou¹, and Gillian M. Tozer¹

¹ Univ. of Sheffield, Sheffield, United Kingdom.

Abstract

Background: Tubulin binding microtubule depolymerising agents form a growing group of tumor vascular disrupting agents (VDAs) in clinical trial, with combretastatin A-4-phosphate (CA4P) the lead compound. Signalling through RhoGTPase/ROCK-dependent pathways is central to CA4P-induced effects on endothelial cells *in vitro* (1). Here, we tested the hypothesis that RhoGTPase/ROCK signalling is also important in tumor vascular damaging effects *in vivo*.

Experimental procedures: SW1222 human colorectal carcinoma cells were grown as solid sub-cutaneous tumors in SCID mice. The Rho kinase (ROCK) inhibitor, Y-27632 (50 mg/kg) or saline vehicle, was administered intraperitoneally (i.p.), 5 minutes prior to 100 mg/kg CA4P or saline i.p. Laser Doppler flowmetry was used to assess tumor vascular response from 0 – 2h post-treatment, under isoflurane anaesthesia. Intravenous administration of fluorescent tomato lectin was used for assessing tumor perfusion at 1, 3, 6 and 24 hours post-CA4P/saline treatment, unanaesthetised. Necrosis (H&E) and leukocyte infiltration (immunohistochemistry) were assessed at 24h from excised tumors. Mean arterial blood pressure (MABP) was monitored in unanaesthetised mice without tumors, using a tail cuff system.

Results: Y-27632 alone significantly decreased MABP by 40% but did not significantly affect tumor necrosis at 24 hours (17±4% of tumor sectional area for treated versus 10±3% for controls). Y-27632 alone reduced relative red cell flux in the tumor (laser Doppler flowmetry) by approximately 50%, which was similar to the reduction observed for CA4P alone. However, pre-treatment with Y-27632 did not affect CA4P-induced laser Doppler or perfused vascular volume measurements in the first few hours after CA4P and significantly reduced the effect of CA4P on perfused vascular volume and necrosis measured at 6 and 24 hours. Necrosis was 61±5% for CA4P alone and 35±7% for Y-27632+CA4P. These changes were accompanied by a decrease in staining for the myeloid markers, myeloperoxidase and GR-1 with Y-27632 pre-treatment.

Conclusions: The Y-27632-induced decrease in MABP is consistent with the decrease in relative red cell flux in the tumor, via a decrease in tumor perfusion pressure. Despite these effects of Y-27632 alone, its administration prior to CA4P was protective of CA4P-induced vascular damage at the later time-points, suggesting that ROCK inhibition is acting downstream from initial vascular shut-down, potentially via modulation of myeloid cell recruitment. These data indicate that RhoGTPase/ROCK-dependent signalling is a critical factor in determining extent of vascular disruption by CA4P – these results have significance for similar VDAs in development.

References

(1) Kanthou C. & Tozer GM, 2002, Blood 99: 2060-2069.

Funded by Cancer Research UK